Skanska to build new facility for Immunex Corporation worth USD 500 M

Press Release

 

2001-01-11

  Skanska to build new facility for Immunex Corporation worth USD 500 M   Sordoni Skanska has been selected by Immunex Corporation to build the company’s new headquarter and research and development facilities in Seattle, WA. The value of the construction is more than USD 500 million, or SEK 4.7 billion. Groundbreaking is expected to take place at the end of January. The assignment will be Skanska’s largest house construction project to date. The site, formerly known as Terminal 88, on the Seattle waterfront covers 29 acres. The project includes Immunex’s new research and development laboratories as well as corporate headquarters, all serviced by a new central utilities building. Immunex Corporation is a biopharmaceutical company dedicated to improving lives through immune system science innovations. Sordoni Skanska, a member of Skanska USA Building Inc, is a well-known leader in biopharmaceutical and pharmaceutical construction. Sordoni Skanska’s long list of pharmaceutical clients includes American Home Products, Aventis, Hoffman-LaRoche, Merck, Schering-Plough, Pfizer and Pharmacia. __________________________________________________ For further information, contact: Caroline Bucquet, Communication Manager, Sordoni Skanska, Tel: +1 973 334 5300 Tor Krusell, Head of Communications, Skanska AB, Tel: + 46 70 543 87 47